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ABSTRACT 
 
Extracts from the root bark, stem bark, and leaves of R. natalensis were screened for antibacterial 
activity against standard bacterial strains; Staphylococcus aureas, Escherichia coli and 
Pseudomonas aureginosa, and fungi; Candida albicans, Trichophyton mentagrophytes or 
Microsporum gyseum. Chromatographic techniques were utilized to isolate pure compounds.  
This study validates and documents, in a systematic way, the antimicrobial properties of the R. 
natalensis used for many years by many people of the world. It also provides valuable 
information for further phytochemical isolation and characterization studies of active 
compounds, necessary for the development of new drugs. The extractions were carried out using 
broad spectrum of solvents (hexane, dichloromethane, ethyl acetate, and methanol). 
Fractionation was done using standard chromatographic techniques. A total of seven (7) 
compounds were isolated from R. natalensis. Three of the isolates were characterized and their 
structures were unambiguously established by detailed spectroscopic analysis that involved high 
resolution mass spectrometry, 1D and 2D-NMR spectral data experiments 1H, 13C, DEPT, 
COSY, HMBC, and NOESY. These compounds are: 3-(1-(2,4-dihydroxyphenyl)-3,3-bis(4-
hydroxyphenyl)-1-oxopropan-2-yl)-7-methoxy-4H-chromone-4-one (39), Rhuschromone, a 
novel compound isolated for the first time, 2’,4’-dihydroxychalcone-(4-O-5’’’)-4’’,2’’’,4’’’-
trihydroxychalcone (40) and 3-((Z)-heptadec-13-enyl) benzene-1,2-diol (41), an urushiol. 
Compound 39 recorded the highest activity zone of inhibition (21mm) against S. aureas, which 
was found to be 50% as active the chloramphenicol standard used. The traditional use of the 
extracts in infections and inflammatory conditions is rationalized based on the content of the 
isolated compounds, and it has been proposed that the total crude extract, with its contents of so 
many bioactive compounds, could be formulated for use in many infections, microbial or fungal. 
Furthermore, not all of the species studied to date have been fully characterized for potential 
bioactivities. Thus, there remains a significant research gap spanning the range from lead 
chemical discovery through process development and optimization in order to better understand 
the full bioactive potential of many of these plants. 
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CHAPTER 1 
                                                               INTRODUCTION 
1.1 Background 
Plant chemistry has developed over the years as a distinct discipline between natural product 
organic chemistry and plant biochemistry. It is concerned with the enormous variety of organic 
substances that are elaborated and accumulated by plants and deals with the chemical structures 
of these substances, their biosynthesis, metabolism, natural distribution and biological function. 
 
Medicines from plants contributed largely to human health. A lot of research on plants has led to 
the development of many drugs and plants are a good source for the present and the future.  
However, continued use of crude extracts without scientific evaluation may lead to serious 
complications such as overdose, and lack of awareness about the presence of toxic substances 
that would otherwise poison the body cells.  The manner in which drugs are handled is important 
to ensure that they do not lose their potency.  Upon expiration, harmful products may be formed 
and as such, it is necessary to establish a proper scientific procedure for preparation and use of 
such herbal medicines through toxicological, microbial, pharmacological and chemical studies 
(Nkunya et al., 1990). New antimicrobials with related activities and structures but different 
from those currently in use, can be obtained from plants. This requires a follow up with attempts 
to isolate and identify those active compounds. The plant kingdom is rich in, and has abundant 
sources of many remedies for the prevention and cure of various human ailments with minimum 
side effects, as well as maintenance of healthy and normal physiological state (Goswan, 2002). 
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The African continent is known to have a wide variety of indigenous species of plants. By 
making appropriate approaches and investigations of these indigenous resources, very important 
biologically-active compounds could be discovered from the traditional medicinal plants people 
use (Rosenthal, 2001). Up to 70% of our modern drugs are obtained from these natural sources, 
using either the natural substance directly or those synthesized through modern technology 
(Jassim et al., 2003). 
 
Plants which have medicinal activities are known to have an advantage of possessing a range of 
chemical diversities of secondary metabolites. Such medicinal properties are often of superior, 
and if not, of similar activity as modern synthetic drugs. A wide range of phytochemicals that 
includes flavonoids, anthocyanins, alkaloids, and coumarins among others, has been discovered 
(Jassim et al., 2003). In Africa, reliance on herbal medicine is very high, as indicated by the fact 
that 70% of the population depends on traditional medicines for their primary health care, despite 
the lack of scientific information on efficacy and side effects (Kokwaro, 1996). This is generally 
due to limited access to the modern health facilities. Poverty further aggravates the situation as 
available medicine is sometimes unaffordable. This situation is true in parts of Africa and a few 
Asian and Latin American countries. Traditional medicine, particularly herbal medicine 
(Nsowah-Nuamah, 2002) has found broad use in these regions. 
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1.2 Microbial infections  
The bodies of mammals act as a favourable environment for the growth of numerous micro-
organisms. The multiplication of these micro-organisms result in an unfavourable interaction 
leading to diseases. Further complications arise from those which are able to make harmful 
chemicals that act like acids or poisons. At times microbial infections are so irritating to the body 
systems such that our own body’s defense overcompensates and attack not only the bacteria but 
also the tissues that host them. Bacterial infections usually make one to be noticeably sick, 
whether it’s an infected toe nail or bloody diarrhoea (Hensley et al., 2004).  
 
As much an infection may be obvious, it requires a modern laboratory to identify the exact germ 
such that the correct treatment may be prescribed.  Most microbes can be grown in the laboratory 
and tested for their reaction to different antibiotics. This is why a specimen must be collected 
from an infected individual (Shlaes et al., 2002). Pneumococcal and Influenza infections are the 
most common causes of acute respiratory infections in children.  Except for a few cases like 
BCG (Bacillus of Camette and Guerin), vaccines have not been developed for all bacterial 
infections and so far, no anti-fungal vaccines are known. This is the reason why 
chemotherapeutic agents are necessary (WHO, 1996). It is to be appreciated that the introduction 
of antimicrobial agents into general clinical use represents one of the landmark medical advances 
of modern medicine. However, the issue of antimicrobial resistance has become a concern 
recently. The resistance of bacteria and fungi to current antimicrobial agents is a worldwide 
medical problem (WHO 2004). Currently, there are recurring multiple drug resistance (MDR) 
outbreaks in the developing worlds (WHO 2004).  
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More than 70% of the bacteria causing infections have become resistant to some particular drugs 
(WHO 2004). The situation has been made worse by the prevalence of the HIV/AIDS pandemic, 
poverty and an emergence of new infectious diseases like swine flu and Ebola, high costs and 
side effects of the available drugs. This has resulted in increased severity of such infectious 
diseases and the high mortality rate from certain infections. All these factors have necessitated 
studies on the potential sources of effective, safe and cheap antimicrobial alternatives. Such have 
been found to originate from plants and these have not been exhaustively exploited (Thangadurai 
et al., 2004). This review will examine the history of antimicrobial drug development, how it has 
influenced the present situation, where we stand today as in terms of turning into natural 
medicine from plants, and it shall also address some of the potential solutions for spurring future 
antimicrobial development. 
 
1.3 Antibacterial drugs 
The past uses of antibacterial drugs have generated issues associated with their safety. In fact, 
safety issues associated with antimicrobials have changed the face of public health. The deaths 
associated with use of some types of sulfonamides resulted in the establishment of the Food, 
Drug and Cosmetic (FD&C) Act in 1938 (Munson et al., 1995). During the 30 years following 
the introduction of penicillin and sulfonamides, scientists discovered and developed a wide range 
of antimicrobials to treat bacterial diseases, presenting clinicians with a number of treatment 
options for most infectious diseases. The method of discovery of new agents was largely based 
on the methods of scientists working and evaluating naturally occurring compounds.  
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Many new antimicrobials have been discovered serendipitously, and by observation of various 
experimental works, many other such drugs have been developed by chemical modification of 
existing agents (US FDA., 2004). The discovery of new classes of antibacterial drugs, defined 
here as drugs with a completely novel mechanism of action, had slowed down. For the last novel 
class of antibacterial drug discoveries during the modern times, the majority of these have 
consisted of chemical modifications of previously discovered classes of drugs. This is testament 
to the challenges inherent in the discovery of new agents.  
In spite of a lack of new classes of agents, drug developers have continued to introduce new 
agents within existing classes. Some of these agents have efficacy against diseases caused by 
pathogens that were resistant to previous 'generations' of the same class. In addition, some of the 
drugs have demonstrated improved efficacy in certain diseases compared with previous drugs. 
For instance, third generation cephalosporins (Williams, 1987) are effective in diseases caused 
by Gram-negative organisms and in diseases, such as acute bacterial meningitis, where first-
generation cephalosporins were less effective. Other agents had similar efficacy but manifested a 
different safety profile or a more convenient dosing schedule. Other agents introduced during 
this time represent major advances over previous agents within the class and do present 
clinicians with an expanded range of treatment options. 
Antibacterial drugs should be used only if clinical or laboratory evidence suggests bacterial 
infections. Use of these drugs for viral illnesses is inappropriate; it subjects the patients to drug 
complications without any benefit and contributes to bacterial resistance. Certain bacterial 
infections (abscesses, infections with foreign bodies) require surgical intervention and do not 
respond to antibiotics alone (Reichert et al., 2003).  
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Culture and antibiotic sensitivity tests are essential for selecting a drug for serious infections. 
These are diagnostic laboratory procedures used to identify the type of bacteria and to determine 
which antibiotics can successfully fight an infection. The absence of bacteria does not mean 
there is no infection, since it could be a virus that will not grow in a specific culture medium. 
Treatment, however, must begin once culture results are available, necessitating selection 
according to the most likely infecting organisms. Depending on the culture results, drugs used 
(DiMasi et al., 2003) should possess the narrowest spectrum of activity that will control the 
infection.  Treatment of a serious infection that may involve any one of several pathogens or due 
to multiple pathogens like polymicrobial anaerobic infection, a broad spectrum of activity is 
desirable.  The most likely organisms and their susceptibility to antibacterial effects vary 
according to their geographical location.   
 
Antibacterial drugs kill bacteria in vitro. Bacteriostatic drugs slow or stop in vitro bacterial 
growth but recovery depends on body defenses to kill them. Quantitative methods identify the 
minimum in vitro concentration at which an antibiotic can inhibit growth or kill such bacteria. 
However, in vivo antibacterial effectiveness involves other factors including pharmacology 
(Boggs et al., 2004) i.e. absorption, distribution, concentration in fluids and tissues, protein 
binding and rate of excretion or metabolism, presence or absence of drug interactions or 
inhibiting substances and host defense mechanisms. Usually greater in vitro killing power is 
important only if local or systemic host defenses are weak, for example in endocarditis, 
meningitis, serious infections in netropenic or other immune–compromised patients.  
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The predominant determinant of bacteriological response to antibiotics (Spellberg et al., 2002) is 
either the duration that blood levels of the antibiotic exceed minimum inhibitory concentration 
(time dependence) or the peak blood level relative to minimum inhibitory concentration 
(concentration dependence). This avoids subjecting a patient to drug complications and 
contribution to bacterial resistance. Many antimicrobials are prescribed for treatment durations 
ranging from a single dose to 10 days of treatment. This short-term use limits the potential 
profitability of antibacterial drugs compared with other classes of drugs. Some of these drugs 
include the following 
 
1.3.1 Penicillin 
Penicillins refer to a group of beta-lactam antibiotics used in the treatment of bacterial infections 
caused by Gram–positive bacteria. They inhibit bacterial growth by interfering with the 
transpeptidation reaction of bacterial cell wall synthesis. Penicillin is used in reference to a 
specific member of the penicillin group Penam skeleton. The basic nucleus of penicillin is 6-
aminopenicillanic acid (1) 
 
NH
S
O
O
OH
H2N
1  
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An example of narrow spectrum penicillin along with a poor oral activity is penicillin G (2). 
These led to the search for derivatives of penicillin that could treat a wider range of infections.  
  
H2
C
N
H
N S
O
O
O
OH
2  
 
1.3.2 Sulphonamides 
Sulphonamides are one of the oldest groups of antimicrobial compounds. These were the first 
antimicrobial agents to be used in the treatment of human systemic infections (Mandell, et al., 
2003). Chemically useful sulphonamides are derived from sulphonamide by substitution of the 
amide moiety such as in sulphadiazine (3). There have been human body side effects resulting 
from sulphonamide residues.  Some of these are headaches, mental depression and vomiting. 
 
O
S
H
N
N
N
NH2
O
3
 
                                                                             
1.3.3 Fluoroquinolones 
These antimicrobials are used to treat infections caused by bacteria. Physicians prescribe these 
drugs for bacterial infections in bones and joints, skin, urinary tract and some sexually 
transmitted diseases, and opportunistic attacks that affect people with HIV/AIDS among other 
diseases.  
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Continued attempts to produce compounds with significant chemical novelty and patentability 
have become extremely a great challenge. A number of avenues have been explored in order to 
cover new ground including discoveries from plant medicine. There are, however, some 
available drugs, both in tablet or injectable forms. Some examples of such chemical structures of 
the fluoroquinolone antibiotics are ciprofloxacin (4), moxifloxacin (5) and ofloxacin (6) 
(Knowles, 1997). 
 
O
N
F
N
NH
O
HO
4    
O
N
F
O
HO
O
CH3
N N
5   
O
N
F
O
HO
O
N
N
CH3H3C
6                             
 
The most common side effects of fluoroquinolones are nausea, skin rashes, vomiting, insomnia, 
diarrhoea, dizziness, photosensitivity and abnormal liver function. Due to some serious side 
effects that lead to fatalities, some drug varieties under this category of antimicrobials have been 
banned (Frothingham, 2004).  
 
1.3.4 Tetracyclines 
Tetracyclines act by inhibiting protein synthesis after uptake by active transport of the 
susceptible organism (Catlin et al., 1982). Tetracyclines chelate calcium and deposit in growing 
bones and teeth causing staining and sometimes dental hyperplasia. High doses of tetracyclines 
are known to decrease protein synthesis in host cells.  
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Examples of tetracycline broad-spectrum of antibiotics include oxytetracycline (7), deoxycycline 
(8), and minocycline (9). 
 
H2N
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OOO OHOH
N
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OH
H OH
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7   
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1.4 Antifungal drugs 
Antifungal drugs are of two kinds, systemic and topical. Systemic antifungal drugs are medicines 
taken orally or by injection to treat infections whereas topical antifungal drugs are those applied 
to the skin to treat skin infections (Espinel-Ingroff et al., 1989). Common fungal infections 
include athlete's foot, jock itch, candidiasis (also called thrush or yeast infection).  
 
Topical antifungal drugs not only relieve the symptoms of fungal infection, such as itchiness, 
burning, and cracked skin, but they also eliminate the fungus. However, fungi which do not clear 
up after treatment with creams or ointments may need to be treated with systemic antifungal 
drugs (Groll et al., 1998). This category of drugs is available even without a physician's 
prescription and come in many forms, including creams, ointments, liquids, powders, aerosol 
sprays, and vaginal suppositories (Cuenca et al., 2007). Creams and liquids are usually the most 
effective for treating fungal infections on the skin, because they can get into the cracks and 
crevices where fungi grow.  
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On the other hand, powders absorb moisture and hence they are good to use in moist areas of the 
body, such as between the toes (Fitzpatrick et al., 2006). Systemic antifungal drugs work best 
when the amount of medicine in the body is kept constant. This means that the medicine has to 
be taken regularly. Medicine should be taken at the same time every day, and one should not 
miss any doses. During the course of taking such medicines, it is recommended that treatment be 
reviewed as often as possible. There is every need to keep checking for side effects throughout 
the antifungal therapy. Taking systemic antifungal drugs with certain other drugs may affect the 
way the drugs work or may increase the chances of side effects. The most common minor side 
effects of systemic antifungal drugs are constipation, diarrhoea, nausea, vomiting, headache, 
drowsiness, dizziness, and flushing of the face or skin. These problems usually go away as the 
body adjusts to the drug and do not require medical treatment (McCullough et al., 1999). The 
recommended dosage depends on the type of antifungal drug and the medical problem for which 
the drug is being taken. Doses may also differ from one patient to the next. Fungal infections can 
take a long time to clear up, so it may be necessary to take the medicine for several months, or 
even for a year or longer (Bougnoux et al., 2004). Commonly used antifungal drugs are in the 
following sections (1.4.1 and 1.4.2)  
1.4.1 Amphotericin B 
This is a macrolide of broad spectrum activity. It is very active against most fungi and yeasts, 
both superficial on exposed organs and systemic infections, affecting deeper tissues and organs. 
Orally administered amphotericin B is poorly absorbed (Bunow et al., 1997). Serious side effects 
of amphotericin B are its real toxicity towards the reduction of renal function, impaired hepatic 
function and anaphylactic reactions. Unfortunately, the drugs which suppress these adverse 
reactions are very expensive (Barnes et al., 2003).  
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The recently discovered amphotericin B (10), a lipid complex, is less toxic especially towards 
renal organs.    
HO
H3C
OH
OH OH OH OH O
H3C O
O
OH
COOCH3
H
OH
OH
O
OH
CH3
OH
NH2
O
H
10  
 
1.4.2 Flucytosines 
These are used only in combination with amphotericin B or the azoles because of the high rate at 
which the target microbes may develop resistance. Extreme caution is needed in their usage since 
they cause renal impairments (90% excreted unchanged in urine). Examples of these drugs 
include imidazoles like; 1, 2-diazole (11) and 1, 3-diazole (12) among others (Cuenca et al., 
2007). 
N
H
N
H
H
H
11                                   
N
H
N HH
H
12  
                                                                                                                                                                                  
Emergence of some limitations of these azoles involves their susceptibility to resistance by 
fungal organisms like Candida species. Medicinal plant research studies are being undertaken 
worldwide in order to help overcome these limitations by providing alternative drugs (Jassim et 
al., 2003).    
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1.5 Antiviral drugs 
The development of antiviral drugs may be looked at on a comparative basis with that of 
antibacterial (Mandel et al., 2003). Since there are far fewer antiviral drugs already available 
than antibacterial, there is less competition. Many antiviral drugs are for chronic illnesses like 
HIV/AIDS, and are prescribed on a long-term basis for the life of the patient. There is less 
likelihood of inappropriate prescriptions, at least with some antiviral, such as anti-HIV drugs, 
since diagnostic tests can accurately select patients who require treatment, and the need for 
immediate treatment is less in a chronic illness than in a bacterial disease that may be rapidly 
fatal. Consequently, there has been an increase over time in the number of FDA approved 
antiviral drugs (Srinivasan et al., 2004).  
The discovery of antiviral drugs has not been very easy, but lead compounds have been modified 
in relation to the target in order to come up with varieties having improved bioactivity. Examples 
of some of the antiviral drugs are: Acyclovir (13), and Gancyclovir (14).  
HN
N N
N
H2N
O
OH
O
13
           
HN
N
N
N
H2N
O
OH
O
14  
            
The problems associated with most of these drugs are their toxicity levels in that they have many 
side effects, for example, Acyclovir (13) that causes anaemia. Resistance to antiviral action also 
increases with prolonged use. Another factor that leads to the decline in their efficiency is 
increased viral load as a result of reduction in the immune mechanisms (Piscitelli et al., 2003). 
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Due to rapid mutation of the virus, more complications arise towards their control (Rocco et al., 
1999). Attempts to obtain more curative drugs with minimal resistance or none at all may 
involve working on medicinal plants found in nature. 
 
1.6 Statement of research problem 
Medicinal plants are important elements in traditional medicine in all cultures of the world. The 
idea that certain plants had healing potential was known long before human beings discovered 
the existence of pathogens. Medicinal plants which have been used by man to treat common 
diseases are important elements of traditional medicine.  In recent years, traditional medicine has 
not been limited to a specific culture. It has been used in developing countries as well as in 
developed countries. Effects of HIV/AIDS, HBV, Ebola and other microbial attacks have 
worsened the situations and there is need to explore those plants that can offer medicinal value. 
The proposed investigation here seeks to isolate and determine structures of various bioactive 
metabolites from some species of the genus Rhus in the family of Anacardiaceae. 
 
1.7 Justification 
In various countries both in Africa as well as Europe, medicinal plants are important elements of 
indigenous medical systems. 70-80% of Africans depend on herbal drugs and traditional 
medicines for primary health care. Africa possesses a large number of plants, which have the 
potential for therapeutic applications in modern medicine. Varieties of the plants are known to 
traditional healers in many communities and are being used by them in therapy. Many plants 
used in our traditional therapy have not been well studied in order to understand their efficiency, 
safety and activity.  
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When such active components are known, they may be isolated and their structural modification 
performed so as to synthesize more derivatives. The bioactive compounds can thus be used as 
templates for synthesizing novel drugs for clinical use (Murray, 1995). The potential for side 
effects and development of drug resistance make research based on natural resources such as 
medicinal plants ever more important.  
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1.8 Hypotheses 
i) Plants from the genus Rhus may contain unique compounds with  
antibacterial and antifungal activity. 
ii) Such compounds may be stable and can be isolated and identified. 
iii) Compounds isolated may remain bioactive once isolated from the  
     plant sources. 
 
1.9 Objectives 
1.9.1 General objective 
Isolation and structural elucidation of secondary metabolites from selected  
species of the genus Rhus 
 
1.9.2 Specific objectives 
i) To perform sequential extractions on a selected species of the genus  
Rhus; R. natalensis. 
ii) To determine the antimicrobial activity of the crude extracts. 
iii) To isolate pure compounds from the crude antimicrobial fraction using  
chromatographic techniques. 
iv) Determine the structures of the compounds using spectroscopic techniques 
(e.g. UV, NMR, COSY techniques). 
v) Determine antimicrobial activity of the isolated pure compounds 
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CHAPTER 2 
 LITERATURE REVIEW 
 
2.1 The family Anacardiaceae 
This research focuses on the Anacardiaceae family which includes plants that produce gums, 
resins or latex from which antimicrobial compounds may be isolated.  The special focus for this 
research is the Rhus genus.  These are plants having trifoliate leaves with small flowers that 
eventually produce fruits which are in the category of drupes.  Rhus natalensis is a shrub with a 
smooth dark brown bark. The leaflets are elliptic or obvate with rounded apex. Their leaf 
margins do crenate at times. They produce cream or greenish yellow flowers that eventually bear 
green fruits, round in shape. Plate 1 shows a part of the plant under study. The plant is common 
in wooded grassland thickets or grasslands with rocky sites. In the different regions of Kenya, 
the plant has different traditional names, and it is widely recognized by the indigenous people for 
treating various conditions. The vernacular names include Mutheo (Kamba), Muthigiu (Kikuyu), 
Siriat (Kipsigis), Sangala–madongo (Luo), Olmisigiyioi (Maasai), Murimuthu (Meru). The fruits 
are edible; a decoction of the fruit is employed against diarrhoea (Henk, 1991).  
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 Plate 1. Photograph of Rhus natalensis.  
1. Rhus natalensis
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2.2 The genus Rhus 
Rhus plants are flowering plants in the family Anacardiaceae (USDA, 2007) found in temperate 
and tropical regions worldwide. Representative members by their geographical locations are 
listed in Table 1. In general, Rhus plants can grow in non-agriculturally viable regions, and 
various species have been used by indigenous cultures for medicinal and other purposes (Van 
Wyk et al., 2004). They often grow in areas of marginal agricultural capacity, and have a long 
history of use by indigenous people for medicine and other applications without necessarily 
competing with food production in terms of land use. Research undertaken on Rhus extracts to 
date indicates a promising potential for this plant group to provide renewable bioproducts with 
the following reported desirable bioactivities; antimicrobial, antifungal, antiviral, antimalarial, 
antioxidant, antifibrogenic, antiinflammatory, antimutagenic, antithrombin, antitumorigenic, 
cytotoxic, hypoglycaemic, and leukopenic. Furthermore, the bioactive components can be 
extracted from the plant material using environmentally benign solvents that allow for both food 
and industrial end-uses. The favorable worldwide distribution of Rhus also suggests that 
desirable bio-products may be obtained at source, with minimal transportation requirements from 
that source, through processing to end consumer. However, not all of the species studied to date 
have been fully characterized for potential bioactive components and bioactivities.  
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Table 1. Geographic distribution of member representatives of the genus Rhus.           
Asia 
R. chinensis (Chinese Sumac)  
R. hypoleuca  
R. javanica  
R. punjabensis (Punjab Sumac) 
R. verniciflua  
Australia  
R. taitensis  
Mediterranean  
R. coriaria (Tanner's Sumac)  
R. pentaphylla  
R. tripartita  
Mexico and Central America 
R. muelleri (Müller's Sumac)  
Pacific Ocean  
R. sandwicensis  
Africa  
R. acocksii  
R. albomarginata  
R. angustifolia  
R. batophylla  
R. baurii 
Africa cont’d 
R. lucida 
R. macowanii 
R. magalismontana 
R. maricoana 
R. marlothii 
R. microcarpa 
R. montana 
R. natalensis 
R. nebulosa 
R. pallens 
R. pendulina 
R. pentheri 
R. pondoensis 
R. populifolia 
R. problematodes 
R. pterota 
R. pygmaea 
R. pyroides 
R. quartiniana 
R. refracta 
R. rehmanniana 
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Africa cont’d  
R. bolusii  
R. burchellii  
R. carnosula  
R. chirindensis  
R. ciliata  
R. crenata  
R. cuneifolia  
R. dentata  
R. discolor  
R. dissecta  
R. divaricata  
R. dracomontana  
R. dregeana  
R. dura  
R. engleri  
R. erosa  
R. fastigiata.  
R. gerrardii  
R. glauca  
R. gracillima  
R. keetii  
R. krebsiana 
Africa cont’d 
R. rigida 
R. rimosa 
R. rogersii 
R. rosmarinifolia 
R. rudatisii 
R. scytophylla 
R. sekhukhuniensis 
 R. stenophylla 
 R. tenuinervis 
 R. tomentosa 
 R. transvaalensis 
 R. tridactyla 
 R. tumulicola 
 R. undulata 
 R. volkii 
 R. wilmsii 
 R. zeyheri 
R. gueinzii  
R. harveyi  
R. horrida  
R. grandidens  
R. kirkii  
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The genus Rhus is of great interest since its members have been found to possess chemical 
compounds that are toxic to micro–organisms.  The compounds include flavonoids, biflavonoids, 
and isoquinolines among others. The genus Rhus consists of over 200 species and is known to be 
rich in biflavonoids and urushiols.  Interest in biflavonoids has increased in recent times due to 
realization of a variety of biological activities manifested by them (Lin et al., 1999).  
 
Africa cont’d 
R. laevigata  
R. lancea  
R. leptodictya  
R. longispina  
R. lucens  
R. incisa  
North America 
R. aromatica (Fragrant Sumac) 
 R. choriophylla (Mearns Sumac) 
 R. copallina (Winged Sumac) 
R. lanceolata (Prairie Sumac) 
 R. incisa R. laurina (Laurel Sumac) 
 R. michauxii (Michaux's Sumac) 
 R. microphylla (Desert Sumac) 
North America cont’d 
  R. ovata (Sugar Sumac) 
 R. trilobata (Skunkbush Sumac) 
 R. typhina (Staghorn Sumac) 
 R. toxicodendron 
 R. vernix 
 R. virens (Evergreen Sumac) 
R. glabra (Smooth Sumac) 
 R. integrifolia (Lemonade Sumac) 
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The root methanol extract from Rhus succedonea has been reported to contain compounds such 
as agathisflavone (15) robustaflavone (16) hinokiflavone (17) volkensiflavone (18) rhusflavone 
(19) succedaneflavone (20) and their methyl ethers and acetates. 
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Compounds 16, 18, 19, and 20 were evaluated for their antiviral activities and 16 exhibited 
strong inhibitory effects against influenza A and influenza B viruses (Lin et al., 1999). The same 
activity was demonstrated by compounds 15 and amentoflavone (21) which also exhibited 
moderate anti-Herpes Simplex Virus (HSV)-I and anti-Herpes Simplex Virus (HSV)-2 activities 
(Lin et al., 1991). Some biflavonoids from Rhus succedonea as well as their methyl ethers have 
shown anti HIV-I reverse transcriptase activity. The biflavonoids responsible for this are 
compounds 16 and 17. Morelloflavone (22) has also demonstrated significant antiviral activity 
against HIV-1 (strain LAV-1) in phytohemagglutinin-stimulated primary human peripheral 
blood mononuclear cells (Lin et al., (1999).   
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Recent studies have examined a broad spectrum of antiviral properties of Rhus extracts, and the 
work focused on biflavonoids isolated from the seed kernels of R. succedanea (Lin et al., 1999). 
Six of the biflavonoid compounds 14, 15, 18, 19, 20 and 21 were isolated from R. succedanea 
seeds and tested for inhibitory activities against a number of viruses namely respiratory viruses 
(influenza A, influenza B, respiratory syncytial, para-influenza type 3, adenovirus type 5), 
measles and herpes viruses (HSV-1, HSV-2, HCM, and VZV). The results indicated that 
compound 16 exhibited strong inhibitory effects against influenza A and influenza B viruses 
whereas compounds 15 and 21 had only an insignificant activity.  
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Compounds 16 and 21 had moderate anti-HSV-1 and anti-HSV-2 activities. Compound 19 
inhibited influenza B measles and HSV-2 viruses, while compound 20 inhibited influenza B 
virus and VZV. It is also noteworthy that compound 21 has been reported in R. retinorrhoea 
leaves (Ahmed et al., 2001) and compound 15 in R. semialata leaves (Bagchi et al., 1985), 
suggesting that other Rhus species may contain antiviral constituents. The literature strongly 
suggests the potential for useful antimicrobial, antifungal, and antiviral agents obtained from 
Rhus extracts, but much work to date has been focused on one species and plant part, that is, the 
fruits of R. coriaria, given its use as a spice. This focus is understandable, but as with the other 
bioactive properties highlighted above, future efforts should include a worldwide survey of Rhus 
genus in order to determine if these properties are generalizable across the genera. Furthermore, 
since the bioactivities appear to be ascribed to polar compounds extractable with protic solvents, 
additional studies are required in order to determine whether these properties occur in extracts 
from other plant parts such as the stem barks, root barks, and the leaves, and what the optimum 
extraction and storage conditions are to obtain the highest quality yields of desired functionality. 
 
Among the over 200 Rhus species, six are common in Kenya. These are R. natalensis, R. 
longipes, R.quartinana, R. tenuinorvis, R. ruspolii and R. vulgaris (Kokwaro 1993).  In 
Tanzania, an extract of pounded R. natalensis roots steeped in hot or cold water is taken for 
influenza, abdominal pain and gonorrhea. The root decoction also forms part of a medicine for 
hookworm infestation. The leaves are used as a cough syrup; they are pounded and steeped in 
hot water and the patient drinks the extract. Sometimes the steam from the hot water leaf extract 
is inhaled to cure colds (Kokwaro, 1993). The stem bark methanol extract of R. quartiniana has 
antibacterial activity against gonorrhea and Staphylococcus aureus (Chhabra et al., 1991).  
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Some of the compounds that have been isolated from the plant include anthocyanins, coumarins, 
essential oils, flavonoids, quinines, saponins, sterols and tannins. In Tanzania, dried stem bark is 
used to treat influenza (Chhabra et al., 1991).  In Kenya and Tanzania, a decoction of boiled 
roots of R. longipes is used for the treatment of abdominal pain and indigestion. Also escaping 
vapour from boiled roots is inhaled as a treatment for influenza (Kokwaro, 1993). In East Africa, 
fruits of R. vulgaris are boiled in water and the extract is drunk to stop diarrhoea while stems are 
boiled and the extract applied to wounds. The roots mixed with other plants are known to make a 
viable drink for expectant mothers, which are believed to make delivery easy, while it is also 
used for the treatment of infertility (Kokwaro, 1993).  
 
In China, the decoction of all parts of R. chinensis is used for treating Diabetes mellitus.  A 
decoction from the seed is used for malaria and rheumatism management (Duke et al., 1985). In 
Israel, an infusion of dried fruit is used for the treatment of diarrhoea, aching gums, toothaches 
and swollen legs (Dafini et al., 1984), while in Turkey the leaf extract is used for treating animal 
bites.  The leaves are boiled in water and used as part of medicine for peptic ulcers, kidney 
stones, eruptions and bruises (Yeslanda et al., 1995). R. glabra is traditionally used by the 
indigenous people of North America for the treatment of bacterial diseases such as syphilis, 
gonorrhea, dysentery, and gangrene (Erichsen-Brown, 1989). R. coriaria, which grows wildly in 
the region of the Canary Islands over the Mediterranean region to Iran and Afghanistan, is 
commonly used as a spice by grinding the dried fruits with salt, and is also widely used as a 
medicinal herb in the Mediterranean and Middle East, particularly for wound healing (Sezik et 
al., 1991). Among the six species of the Rhus genus commonly found in Kenya, there is not 
much phytochemical studies that have been done.  
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Since these plants have been used traditionally to cure certain ailments, there exists a possibility 
of finding new compounds responsible with the relevant pharmacological properties. 
 
2.3 Bioactivity of Rhus Extracts 
Rhus extracts have been shown to exhibit a wide range of biological activities, as summarized in 
Table 2 in relation to antibacterial, antifungal, and antiviral activities. Rhus extracts are most 
notable for their antibacterial activities, although not much information is available on their 
antifungal and antiviral activities. As part of a screening of over 100 medicinal plants in British 
Columbia (Canada), crude methanolic extracts of R. glabra leaves exhibited both the widest 
zones of inhibition in a disc assay, and the broadest spectrum of inhibition was reflected against 
some of the following  bacterial species tested: Bacillus subtilis, Enterobacter aerogenes, 
Escherichia coli, Klebsiella pneumoniae, Mycobacter phlei, Pseudomonas aeruginosa, Serratia 
marcescens, Staphylococcus aureus, and Salmonella typhi (Saxena et al., 1994). Similarly, in a 
follow-up study, the same methanolic extracts inhibited the growth of the following fungal 
strains: Aspergillus flavus, A. fumigatus, Candida albicans, Fusarium tricuictum, Microsporum 
cookerii, M. gypseum, Saccharomyces cerevisiae, Trichoderma viridae, and Trichophyton 
mentagrophytes (McCutcheon et al., 1994). To the best of our knowledge, work on antiviral 
activities of Rhus extracts has focused on biflavonoids isolated from the seed kernels of R. 
succedanea (Lin et al., 1999) as alluded to earlier in this review. 
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Table 2. Reported biological activities of compounds and fractions extracted from Rhus 
Biological 
activity 
 
Antimicrobial 
 
 
 
Antifungal  
 
 
Antiviral 
 
 
 
 
Cytotoxic 
 
 
Antimalarial 
 
 
 
Antioxidant 
 
 
Anti-
inflammatory 
 
 
 
Species 
 
 
R. retinorrhoea  
R. glabra 
R. coriaria 
 
R. glabra 
 
 
R. succedanea 
 
 
 
 
R. verniciflua 
 
 
R. retinorrhoea 
 
 
   
R. coriaria 
 
 
R. undulate 
 
 
 
 
Plant part 
 
 
Leaves 
Stem 
Seeds 
 
Stem bark 
 
 
Seeds 
 
 
 
 
Stem bark 
 
 
Leaves 
Seeds 
 
 
Leaves  
 
 
Root bark 
 
 
 
 
Compound(s) and/or 
extract type 
 
(a)Ethanol and methanol 
extracts   
(b) Water extract 
 
Methanol extract 
 
 
Robustaflavone (16) 
Amentoflavone (21) 
Volkensiflavone (15) 
Succedaneaflavone (20) 
 
Ethanol extract 
 
 
Methanol extract 
Ethanol extract 
 
 
Methanol extract 
 
 
Dimethyl ether 
 
 
 
 
        
References 
 
Nasar-Abbas 
 et al,. 2004.  
 
Ahmed et al., 
2001 
 
Towers et al., 
1994 
 
Lin et al.,  
1999 
 
 
 
Kitts et al.,  
2001 
 
Ahmed et al., 
2001 
 
 
Ozcan., 2003 
 
 
Fourie et al., 
1984 
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Biological 
activity 
Antifibrogenic  
 
 
Antimutagenic 
 
 
 
Antithrombin 
 
 
Antitumorigenic 
 
 
 
Hypoglycaemic 
 
 
 
Leukopenic   
 
Species 
 
R. verniciflua 
 
 
R. verniciflua 
 
 
 
R. verniciflua 
 
 
 
R. verniciflua 
 
 
R. coriaria 
 
 
 
R. vernificera 
 
Plant part 
 
Stem bark 
 
 
Heartwood 
stem bark 
 
 
Stem bark 
 
 
Branches and 
leaves 
 
 
Fruits 
 
 
 
Plant sap 
Compound(s) and/or 
extract type 
Butein 
 
 
Garbanzol, sulfuretin,  
fisetin, fustin, and  
mollisacasidin 
 
6-pentadecylsalicylic 
acid 
 
Ethanol extract  
fractionated on  
Sephadex G-150 
 
Methanol extract further 
fractionated with ethyl 
acetate and hexane 
 
Polysaccharide extracts  
 
References 
 
Lee et al., 
2003 
 
Park et al.,  
2004 
 
 
Kuo et al.,  
1991 
 
Lee et al.,  
2004 
 
 
Giancarlo et 
al., 2006 
 
 
Yang et al.,  
2003 
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2.4 Flavonoids  
Flavonoids may be classified into three main categories, namely: flavonoids, isoflavonoids, and 
neoflavonoids. Flavonoids (both flavonols and flavanols) are most commonly known for their 
antioxidant activity. They are the most common group of polyphenolic compounds in the human 
diet and are found ubiquitously in plants (Spencer, 2008). Both flavonols and flavanols have 
shown evidence of health-modulating effects in animals which consume them. These are 
compounds for whose basic skeleton is a 2-phenyl-4-benzopyrone (23), a flavone.  
O
O
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3
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Flavones are the most abundant of the naturally occurring oxygen containing heterocyclic 
compounds. They form the important group of yellow natural pigments; other closely related 
compounds are the 3-hydroxyflavone (24), a flavonol, 2, 3-dihydroxyflavanone (25), a flavanone 
and a flavylium ion (26) for anthocyanins which often occur together with flavones in the same 
plant. 
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A collective term for all these groups of compounds are flavonoids. They occur in higher plants 
as well as in ferns. They carry hydroxyl groups which are usually located at positions 3, 5, 7, 3’ 
and 4’, for example, quercetin (27). There is also a high tendency for flavonoids to occur as 
glycosides (sugar containing molecules) e.g.Kaempherol-7-Rhamnoside (28). 
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2.4.1 Biflavonoids 
Biflavonoids are dimers of monomeric flavonoids. Biological activity of many biflavonoids 
isolated from plants has been found to be largely of an anti-inflammatory nature both in vivo and 
in vitro. The mechanism for their anti-inflammatory action includes inhibition of mast cell 
histamine release (Amella, et al., 1985) and lymphocyte proliferation (Lee et al., 1995).  
Recently, several C-C biflavones were chemically synthesized and some have shown anti 
inflammatory activity.  
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To extend these findings, structurally optimized derivatives such as the C-O-C biflavone (31) 
having a 6-O-7’’linkage have been prepared. Such biflavones are synthesized via intermolecular 
coupling of 6-bromoflavone (29) analogs and 7-hydroxyflavone (30) analogs as key 
intermediates. 
O
O
Br
29     
O
30
HO
O
O
O
O
O 31
O
 
 
Scheme1. Formation of 6-O-7’’ linkages 
 
There also exist other forms of biflavonoids where the coupling of the monomers occurs through 
the 3 and 8’’ positions. The 3, 8’’-biflavonoids were mainly isolated from Garcinia, Rheedia, 
and Allanblackia species (Clusiaceae), and their remarkable pharmacological activities, such as 
antihepatotoxic (Iwu et al., 1987) and bactericidal properties, have been intensely studied and 
reported. Furthermore, manniflavanone (32) was patented for the treatment of diseases resulting 
from disorders of vascular permeability and fragility, and for the prevention of complications of 
diabetes mellitus (Offner et al., 1981). This type of secondary metabolite also exhibits very 
promising analgesic properties, which have to be further investigated (Bittar et al., 2000). This 
class of biflavonoids consists of a flavanone and 3-hydroxyflavanone units and are represented 
by compound 32 and kolaflavanone (33), respectively. Their structures differ only in the 
substitution pattern of the B rings.  
 
 
 
 
 
33 
 
O
O
OH
OH
HO
OH
OMeOH
OH
HO
O
O
32      
O
O
HO
OH
OH
OH
OH
OMeOH
HO
HO
O
O
33
 
 
A great number of biflavonoids reported in the most recent literature are rated for great activity 
against a range of pathologically significant viruses (Lin et al., 1999). For example hinokiflavone 
(17) amongst other natural flavonoids inhibits the pro-coagulant activity of adherent human 
monocytes stimulated by endotoxin and interleukin-1 in vitro (Lale et al., 1996) while others 
have shown cytotoxicity and antimalarial activities (Ahmed et al., 2001). Another class of 
compounds found in the genus Rhus is the bichalcones. For example R. pyroides, a shrub that 
grows to a medium-sized tree and is widely distributed in the eastern parts of Botswana had, its 
twigs investigated, where isolation and characterization of new bichalcones was achieved and 
given the name rhuschalcone (Masesane et al., 2000).  
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In a recent report, five new bichalcones namely: rhuschalcone I (34), rhuschalcone II (35), 
rhuschalcone III (36), rhuschalcone IV (37), and, rhuschalcone V (38) have been recorded. All of 
their structures were determined by spectroscopic and chemical methods. Upon testing, they 
exhibited selective cytotoxicity against some colon tumor cells.  
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2.4.2 Biological activity 
Flavonoids are widely distributed in plants fulfilling many functions including producing yellow 
or red/blue pigmentation in flowers and protection from attack by microbes and insects. The 
widespread distribution of flavonoids, their variety and their relatively low toxicity compared to 
other active plant compounds (for instance alkaloids) suggest that many animals, including 
humans, ingest significant quantities in their diet.  
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Flavonoids have been referred to as "nature's biological response modifiers" because of strong 
experimental evidence of their inherent ability to modify the body's reaction to allergens, viruses, 
and carcinogens. They show anti-allergic, anti-inflammatory (Yamamoto et al., 2004), anti-
microbial (Cushnie et al., 2005) and anti-cancer activity. Consumers and food manufacturers 
have become interested in flavonoids for their medicinal properties, especially their potential role 
in the prevention of cancer and cardiovascular diseases. The beneficial effects of fruits, 
vegetables, and tea or even red wine have been attributed to flavonoid compounds rather than to 
known nutrients and vitamins (Félicien, 2008).                                                                           
 
2.4.3 Health benefits besides antioxidant properties 
In recent times, research conducted on Free Radical Biology and Medicine indicates that inside 
the human body, flavonoids themselves are of little or no direct antioxidant value (Lotito, 2006). 
Body conditions prove to be unlike controlled test tube conditions, and the flavonoids are poorly 
absorbed (less than 5%), with most of what is absorbed being quickly metabolized and excreted. 
The huge increase in antioxidant capacity of blood seen after the consumption of flavonoid-rich 
foods is not caused directly by the flavonoids themselves, but most likely is due to increased uric 
acid levels. An interesting quotation from David, (2007) reads as follows: - "we can now follow 
the activity of flavonoids in the body, and one thing that is clear is that the body sees them as 
foreign compounds and is trying to get rid of them." 
The process of gearing up the body to get rid of unwanted compounds induces the formation of 
the so-called Phase II metabolic enzymes that also help eliminate mutagens and carcinogens, and 
therefore may be of value in cancer prevention. Flavonoids can induce mechanisms that help kill 
cancer cells and inhibit tumor invasion (Ladislaus, et al., 2003).  
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Cancer researchers have found that human subjects who ate foods containing certain flavonoids 
seemed to be protected from developing lung cancer (David, 2007).  Some of the flavonoids that 
have appeared to be the most protective include quercetin (27) and kaempferol (28). Researchers 
have indicated that only small amounts of flavonoids are necessary to see these medical benefits. 
Taking large dietary supplements provides no extra benefit and may pose some risks.  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Reagents, equipment and materials 
3.1.1 Reagents 
Sulphuric acid, acetic acid, p-anisaldehyde, vanillin were bought from Kobian chemicals, 
Nairobi Kenya; Solvents: Dichloromethane, n-hexane, ethyl acetate, chloroform, petroleum 
ether, acetone, toluene and methanol bought from Kobian chemicals, Nairobi Kenya. Analytical 
grade or double distilled solvents were bought from Fluka AG Switzerland. Deuteriated solvent 
MeOH used for spectroscopic analysis was bought from Sigma-Aldrich South Africa. 
 
3.1.2 Equipment 
3.1.2.1 Solvent evaporation 
Solvent evaporation was performed on a Buchi Rotavapor RE 111 with a water bath at 400C and 
14 mbar.  
 
3.1.2.2 Chromatography 
3.1.2.2.1 Thin layer chromatography (TLC) 
Analytical thin layer chromatography was performed on both aluminium and plastic pre-coated 
plates of silica gel 60 F254 with a 0.2 mm layer thickness. Visualization of the TLC spots was 
achieved under UV light at 254nm or 366nm and by spraying with the p-anisaldehyde reagent 
prepared by mixing 0.5ml anisaldehyde mixed with 10ml glacial acetic acid, followed by 85ml 
of chilled methanol and 5ml of 98% sulphuric acid (Randerath et al., 1968).  
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Preparative thin layer chromatography (PTLC) was performed using normal phase silica gel 60 
F254 pre-coated on glass plates (20 x 20), with varying thickness (0.25, 0.5, 1.0, or 2.0 mm). 
Detection was done under UV light at 256 or 366 nm. 
 
3.1.2.2.2 Column chromatography (CC) 
Glass columns (20-25 mm diameter) wet packed with silica gel 60 (0.040-0.063mm) (230-400 
Mesh ASTM, Merck) were used for column chromatography. Size-exclusion chromatography 
was carried out using Sephadex® LH-20 (Pharmacia), eluting with either MeOH or MeOH-
CHCl3. 
 
3.1.3 Spectroscopy 
3.1.3.1 Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectra were measured on Varian-600 NMR machine based at the Department of 
Chemistry at the University of the Stellenbosch, South Africa and a Bruker-300NMR at the 
University of Botswana. Deuteriated methanol (CD3OD) was used as the solvent. Chemical 
shifts were recorded in δ (ppm).  
 
3.2 Plant material 
3.2.1 Plant samples collection and identification 
Plant material was collected in Kenya, near the Thika river within Gatanga division in June 
2008. The three plant parts namely; root bark, stem bark and leaves were dried for a period of 
three months, stored under controlled conditions in order to minimize undue chemical changes. 
The material was ground into a powder prior to extraction.  
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The plant was taxonomically identified by Mr. Simon Mathenge of the Department of Botany, 
University of Nairobi, Kenya. The voucher specimen (HM 2008/01) was deposited at the 
Department of Botany Herbarium, University of Nairobi, Kenya.  
 
3.2.2 Extraction 
The powdered material was extracted sequentially with solvents of increasing polarity starting 
with hexane (C6H14), dichloromethane (CH2Cl2), ethyl acetate (EtOAc) and finally methanol 
(MeOH). Each extraction involved maceration for a period of about 48 hours, with three 
repetitions for each solvent except for methanol which was done twice. Occasional swirling was 
done to ensure thorough extraction. The extracts were decanted and filtered using Whatman filter 
paper. The extracts were concentrated under reduced pressure using a rotary evaporator at 
temperatures less than50 oC. Separation and purification of the plant constituents was carried out 
using one or the other of a combination of chromatographic techniques. 
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Scheme 2.  A flow chart for the preparation of the plant extracts 
                                                
Fresh plant material 
Hexane Residue
Ethyl acetate Residue 
Methanol Residue 
DCM Residue 
Main material (4.5kg)-100g 
Aqueous extract 
Drying at room temperature (250C) 
Grinding to powder (root bark=4.5kg) 
100g 
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3.3 Antibacterial and anti-fungal screening tests 
Bioassay of the crude extracts against test organisms was carried out using the agar diffusion 
technique. Micro-organisms used in these tests were obtained from the National Public Health 
Laboratories (NPHL). These included local and standard clinical isolates. The micro-organisms 
used included Gram positive bacteria, Staphylococcus aureas (ATCC 25923), Escherichia coli 
(ATCC 25922) Gram negative bacteria, Pseudomonas aureginosa (clinical isolate). The fungi 
used Cryptococcus neoformans (clinical isolate), Trichophyton mentagrophytes (clinical isolate), 
Penicillium spp (environmental isolate) and Candida albicans. These test strains of bacteria were 
kept refrigerated at 4oC in Muller-Hutton agar slants during the storage period. They were then 
tested biochemically for purity before use (Elgayyar et al., 2000). A colony of each bacterial 
strain was put in some agar slants and incubated for 18 hours at normal body temperature.  
Sterile Petri-dishes containing about 20ml of sterile medium of yeast, malt extracts and glucose 
agar for fungi and nutrient broth agar for bacteria were inoculated with an 18 hour culture of the 
appropriate test organism. After 6 hours, a diluted sub-culture was prepared with a similar broth. 
The plant extract was then dissolved in dimethylsulphoxide (DMSO) and 20μl were loaded onto 
a 6mm filter paper. A standard antibiotic, chloramphenicol 2mg and fluconazole 2mg for the 
fungi were used as controls. The various Petri-dishes were then inoculated with 0.1ml of the 
diluted bacteria or fungi culture directly from the 18 hour broth. The inoculations were then 
spread using a sterile glass rod to avoid contamination and allowed to stand for 2 – 3 minutes in 
a refrigerator which was set at 4 oC. Discs loaded with the plant extracts were then placed onto 
the seeded plates. All the Petri-dishes were then incubated at 37 oC for 24 hours for the bacterial 
pathogens and 3 days for the fungal pathogens.  
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After that period of incubation, antibacterial or antifungal activity was assessed by measuring the 
diameter of all the zones of inhibition which were measured in millimeters, taking triplicate 
values of each by measuring in different directions and then calculating the average, using a 
standard laboratory ruler (Elgayyar et al., 2000).  
 
3.4 Isolation of the pure compounds 
3.4.1 Fractionation of the root hexane extract 
The hexane extract (10.6g) was adsorbed on silica gel and fractionated on a column by gravity 
elution using the following solvent systems; 500ml of 100% hexane, then 250ml volumes of 
mixtures with DCM at the following ratios ( 90:10), (80:20), (70:30), (60:40), (50:50), (40:60), 
(30:70), (20:80), (10:90) and finally 100%DCM. This was further followed by 250 ml volumes 
of DCM-EtOAc mixtures using similar ratios until 100% EtOAc. Finally small portions of 
MeOH were introduced in the mixture with EtOAc up to 15% MeOH (98.5:2.5), (95:5), 
(92.5:7.5), (90:10), (95:15). Fractions collected were analyzed by TLC using hexane-EtOAc 
(7:3). Fractions with similar Rf values were pooled together. The combined fraction from vials 
26-29 (400mg) was loaded onto a sephadex column for further separation. DCM-MeOH (50:50) 
500ml was used as eluent leading to the isolation of compound 41 as a clear liquid (171mg).  
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3.4.2 Fractionation of the EtOAc extract of the root 
The EtOAc extract (69.1g) was adsorbed on silica gel and fractionated on a column by gravity 
elution using the following solvent system; 250ml of 100% hexane, then 250ml volumes of 
mixtures with DCM at the following ratios ( 90:10), (80:20), (70:30), (60:40), (50:50), (40:60), 
(30:70), (20:80), (10:90) and finally 100%DCM. This was further followed by 500 ml volumes 
of DCM-EtOAc mixtures using similar ratios until 100% EtOAc. Finally, small portions of 
MeOH were introduced at 5% intervals in the mixture with EtOAc of up to 50% MeOH; (95:5), 
(90:10), (85:15), (80:20), (75:25), (70:30), (65:35), (60:40), (50:50). 
Fractions collected were subjected to TLC analysis using DCM-MeOH (9.5:0.5) ratio. Pooling of 
fractions with similar TLC profiles was done. The combined fraction from vials 39-51 (800mg) 
upon drying was chromatographed on Sephadex LH-20 using the DCM-MeOH (50:50) ratio. 
Fractions collected were analyzed by TLC in DCM-MeOH (9:1). Preparative TLC using DCM-
MeOH (9:1) gave compounds E2 (10.5mg) and 40 (14.9mg). Re-crystallization and subjecting 
other portions to sephadex column chromatography using DCM-MeOH (50:50), and further 
analysis of the fractions by TLC using DCM-MeOH (8:2) gave a yellow powder (321mg). This 
was further purified by preparative TLC using DCM-MeOH (8:2) ratio. Compounds E3 
(11.2mg) and 39 (13.5mg) were obtained as yellow products. Pooling of combined fractions 
from vials 72-78 (400mg) and subjecting the collection to sephadex column chromatography 
using DCM-MeOH (7:3) as eluent; compounds E5 (12.9mg), a crystalline yellow powder and E6 
(9.9mg), deep yellow crystals, were obtained.     
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CHAPTER 4 
RESULTS AND DISCUSSION   
   
4.1 Crude plant extracts 
The finely ground R. natalensis leaves, stem and root barks were available as shown in table 3. 
Only the root bark and stem bark materials that were subjected to sequential extraction with the 
solvents hexane, DCM, EtOAc and finally MeOH.  
Table 3. Initial weights of the plant collection. 
 
 
 
 
 
Some of the crude concentrated extracts deposited crystals on standing while others remained in 
the form of a paste. The yields obtained are presented in table 4. About 1g of each of these crude 
extracts was set aside for use in bioassays. 
  
Table 4. Summary data for the crude yields. 
Part of the plant    Weight in Kgs 
Root bark                      4.5 
Stem bark                      4.0 
Leaves                          2.0 
Part of plant 
extracted 
 
Hexane 
 
DCM 
 
Ethyl acetate 
 
Methanol 
Root bark 10.6g 13.9g 69.1g 85.2g 
Stem bark 9.6g 16.6g 32.5g 59.6g 
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4.2 Bioassays 
4.2.1 Bioassay of the crude extracts  
Bioassay of the crude extracts against selected test organisms was carried out as described 
previously. The data obtained was used to determine MIC breakpoints. The antibacterial and 
antifungal activities of the extracts in terms of  diameters of inhibition zones were reported as in 
Table 5 
Table 5. Inhibition zones of micro-organisms.  
EXTRACTS/ 
CONC 0.5mg/ml 
TEST MICROORGANISMS/INHIBITION ZONE IN MM  
 Bacteria Fungi 
 Sau Eco Pseudo Penici TM Can Crypto 
1 7 6 9 7 6 6 0 
2 18(0.5) 6 9 6 6 6 7 
3 15(0.03) 7 15(0.03) 7 8 8 7 
4 17(0.015) 6 14(0.015) 10(0.5) 10(0.5) 7 7 
5 6 7 15(0.03) 11(0.5) 7 7 6 
6 14(0.25) 6 10(0.5) 8 6 6 6 
7 7 7 13(0.25) 8 8 7 7 
8 6 6 12 6 6 7 6 
9 20 18 17 - - - - 
10 - - - 18 19 15 16 
Each value is the mean of three replications ± standard deviation in bracket measured in 6mm 
disc diameter. 
KEY: 
1. Root bark DCM 
2. Root bark hexane  
3. Stem bark EtOAC 
4. Stem bark MeOH 
5. Root bark EtOAC 
6. Stem bark DCM 
7. Root bark MeOH 
8. Stem bark Hexane 
9. Chloramphenicol standard 
10. Fluconazole standard 
Test Micro-organisms 
 Sau-Staphylococcus aureus ATCC 25923 
 E. coli-Escherichia coli ATCC 25922 
 Pseudo- Pseudomonas aureginosa clinical 
isolate 
 Can- Candida albicans ATCC 90028 
 Crypto-Cryptococcus neoformans clinical 
isolate 
 Penici-Penicillium spp environmental 
isolate 
 TM-Trichophyton mentagrophytes clinical 
isolate 
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The method of testing the efficacy of the extracts was done by introducing a sample into the 
middle of a bacteria-laden or fungi Petri-dish. Standards were also used in order to compare the 
results. A clear zone indicated bactericidal activity. The larger the diameter of the zone of 
inhibition, the higher the efficacy of that extract. The average data was determined and compared 
to the positive controls used. The inhibition zones against microbial growth are presented in 
Table 5.  The three bacterial test organisms used showed a wide range of activity; P. aureginosa 
(gram negative bacterium) was the most sensitive to all the extracts.  S. aureus (gram positive 
bacterium) that plays a considerable role in skin infections was highly sensitive to the root 
hexane extract with an inhibition zone of 18mm. It showed low sensitivity to the stem hexane 
extract, an indicator that the roots had greater potency. E. coli showed intermediate resistance to 
all the extracts in comparison to the standard chloramphenicol. Values greater than 10mm could 
be considered as reflecting moderate activity. However the differences in susceptibility between 
Gram-positive and Gram-negative bacteria may be due to cell wall structural differences between 
these classes of bacteria. The Gram-negative bacteria cell wall outer membrane appears to act as 
a barrier to many substances including antibiotics (Tortora et al., 2001).  
  
The choice of the fungus C. albicans was made due to the serious systemic infections, it causes 
including the opportunistic infections that are common with HIV positive patients. These various 
crude extracts demonstrated limited antifungal activity. The activity on fungi was much lower 
than that on bacteria. There was no activity recorded at all for the root DCM extract against C. 
neoformans. Moderate activities of the extracts against the fungi were recorded for Penicillium 
ssp at 11mm (0.5) and 10mm (0.5) as well as T. mentagrophytes at 10mm (0.5) which were 
clinical isolates. C albicans and C. neoformans displayed intermediate resistance.  
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However, the antifungal activity was far from comparable (as determined by the zones of 
inhibition) to that of fluconazole used as the standard.  The observed biological activities could 
be due to the flavonoids present in the plant under study, as these compound types have been 
known to posses antibacterial and antifungal activity. Traditionally this plant is used in the 
treatment of oral candidiasis and athlete’s foot. The results show that the methanol and ethyl 
acetate extracts have a greater potential as a source of antibacterial or antifungal agents of natural 
origin. Preliminary phytochemical studies have shown that the aerial and root parts of the genus 
Rhus contain biflavonoids responsible for these antimicrobial activities. 
 
Table 6. Antimicrobial activity of isolated compounds 
Name of extracts Wt Volume of 
DMSO used 
Amount 
/disc 
Antibacterial assay Antifungal Assay 
    Sau Eco Pseudo Can TM Mg 
HM/RN/H/1(41) 
 
5mg 400μl 20μl 9 0 0 0 0 0 
HM/RN/E/2a(40) 
 
5mg 400μl 20μl 17 0 0 0 0 0 
HM/RN/E/4 (39) 
 
5mg 400μl 20μl 21 0 0 0 0 0 
Chloramphenicol 2mg 400μl 20μl 20 18 17 - - - 
Fluconazole 2mg 400μl 20μl - - - 15 12 14 
           
KEY: 
1. Sau-Staphylococcus aureus ATCC 25923 
2. Eco-Escherichia coli ATCC 25922 
3. Pseudo-Pseudomonas aureginosa clinical isolate 
4. Can-Candida albicans ATCC90028 
5. Tm-Trichophyton mentagrophytes clinical isolate 
6. Mg-Microsporum gyseum clinical isolate 
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The results in table 6 showed that the isolated compounds expressed some level of activity 
against the bacterium S.aureus in comparison to the chloramphenicol. Compound 39 showed 
a more pronounced zone of inhibition (21mm) against S. aureus. The compounds did not 
register any activity with E. coli and P. aureginosa. No activity on the fungi was recorded for 
the C. albicans, T. mentagrophytes or M. gyseum as compared to fluconazole standard. 
Comparing these results with those of the crude extracts may suggest that the potency of 
individual compounds is compromised by their isolation or that they were not used at 
sufficient concentrations. On the other hand, it is possible that the more potent compounds 
evaded the isolation process.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               *N/C- not characterized due to loss of the sample. 
                                                Comp’d- compound. 
                                                                                           
 
 
Scheme 3. A flow diagram for the compounds extracted. 
 Root extract 
Vials 26-29 
Ethyl acetate Hexane 
Vials 39-51 
Comp’d 41 
(171mg) 
A clear liquid  
(An urushiol)  
Vials 72-86 
Comp’d 
E5 
12.9mg 
*N/C 
Comp’d 
E6 
9.9mg 
*N/C 
Comp’d 
E2  
10.5mg 
*N/C 
Comp’d 
 40 
14.9mg 
 
Comp’d
E3 
11.2mg 
*N/C 
Comp’d 
 39 
13.5mg 
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4.3. 3-(1-(2,4-dihydroxyphenyl)-3,3-bis(4-hydroxyphenyl)-1-oxopropan-2-yl)-7-methoxy-
4H-chromen-4-one (39) 
Compound (39), was obtained as an amorphous yellow powder, revealing a pseudo molecular 
ion [M+H] + at m/z 524, corresponding to the molecular formula C31H24O8. 
O
HO
OH
HO
OH
O
O
MeO
2
3
4105
6
7
8
9
11
12
13
18
17
16
15
14
19
20
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22
23
24
25
26
27
28
29
30
31
39
A C
A'
B'
B
 
The structure was established on the basis of 1D (1H, 13C and DEPT) and 2D-NMR experiments 
(COSY, NOESY, HSQC and HMBC) (Table 7, Appendix 1a-k). The 1H NMR spectrum 
assigned with the aid of the COSY experiment enabled the distinction of two 1, 4-disubstituted 
aromatic rings that were identical (B, B’) and two 1, 2, 4-trisubstituted (A, A’) aromatic rings. 
Long range interaction of two meta-protons H-6 (δ 6.44, dd, J= 2.1, 2.1Hz) and H-8 (δ 6.28, d, 
J= 2.1Hz) as well as H-15 (δ 6.69, d, J=2.1Hz) and H-17 (δ 6.83, dd, J=2.1, 2.1Hz) were 
confirmed by COSY. A typical singlet for proton H- 2 of the isoflavone moiety was observed at 
δ 8.20, (s) and an AB system with a bridge between H-11 (δ 6.02, d, J=12Hz) and H-19 (δ 4.67, 
d, J= 12.0 Hz) were detected. There was long range coupling between the methine proton at H-
19 (δ 4.67, C- δ 54.5) and H-21/H-25 (δ 7.15, C-129.9) of the two aromatic identical rings B and 
B’ which are interchangeable, hence the rings are related to that methine group by 3J (figure 1a). 
The upfield part of the 1H NMR spectrum showed one methoxy resonance at δ3.76.  
 
 
 
 
50 
 
The location of this methoxy substituent in the A- ring was deduced on the basis of NOESY 
enhancement between proton H-6 (δ 6.4, dd, J=2.4, 2.4Hz) and H-8 (δ 6.28, d, J=2.4Hz). The 
methoxy group showed through-space interaction with two protons only, and these were meta-
coupled to each other (figure 1b). Proton H-6 (δ 6.44, dd, J=2.4, 2.4Hz) showed a NOESY 
relationship with the proton H-5 (δ 8.21, d, J=3.9Hz). Another important NOESY was observed 
between H-2 (δ 8.20, s) and H-11 (δ 6.02, d, J= 12.0Hz) then H-19 (δ 4.67, d, J= 12Hz) with H-
21/25 (δ 7.15, d, J= 9.0Hz). Proton H-21/25 (δ 7.15, d, J= 9.0Hz) with H22/24 (δ 6.57, d, J= 
8.4Hz). Aromatic protons were observed at; δ 8.21 (d, J=3.9Hz, H-5), δ 6.44 (dd, J=2.4, 2.4Hz, 
H-6) and δ 6.28 (d, J=2.4Hz, H-8). The 2, 4-dihydroxyphenyl signals in ring A’ were observed at 
δ 6.69 (d, J=2.1Hz, H-15), δ 6.83 (dd, J=2.1, 2.1Hz, H-17), and δ 7.87 (d, J=8.7 Hz, H-18). The 
protons H-11 and H-19 were found to be in a trans-conformation due to their J value of 12.0 Hz 
(Ghogomu et al 1987). The assignment of H-11 was confirmed from HMBC’s with C-2 (δ 
157.5), C-3 (δ 122.6), C-4(δ 177.2), C-12 (δ 205.4), and C-13(δ 135.9). Similarly H-19 was 
confirmed from HMBC’s with C-11(δ 45.1), C-12(δ 205.4), and C-21/25 (δ 129.9). 
13C NMR spectrum showed the typical methine signals for C-11, C-19 at δ 45.1 and δ 54.5 
respectively and this was confirmed by HMQC. There were two carbonyl signals at δ205.4 and δ 
177.0. Other carbons bearing oxygen atoms appeared between δ 156.8 to δ 168.9. H-11 (δ 6.02, 
d, J= 12Hz) showed connectivity to the A, C isoflavone ring moiety.   The B, B’ identical rings 
were bound together to C-19 (δ 54.5). The carbonyl group at δ 205.4 was linked to ring A’ and 
the methine at C-11. The 13Cspectrum displayed signals for 31 carbons which were edited by 
DEPT into 1 methyl, 17 methines and 13 non-protonated carbons consisting of some two 
carbonyls and 9 oxygenated carbons. Detailed analysis of the HMBC and HMQC data enabled 
the complete assignment of the proton and carbon signals leading to the new structure 39. 
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Table7. 1H NMR and 13C NMR data of compound 39 in CD3OD at 300MHz   
 
Position 
1H NMR 
(δ multiplicity, J) 
13C 
NMR   
(δ) 
COSY HMQC  HMBC 
2 8.20 (s) 157.5  8.20  
3  122.6    
4  177.2    
5 8.21 (d, J= 3.9) 134.1 H-6 8.21 C-4, C-7, C-9 
6 6.44 (dd , J= 2.1, 2.1) 108.6 H-5,8 6.44 C-8, C-10 
7  166.9    
8 6.28 (d, J= 2.1) 101.9 H-6 6.28 C-6, C-7, C-10 
9  159.5    
10  115.2    
11 6.02 (d, J= 12.0) 45.1 H-19 6.02 C-2, C-3, C-4, C-12, C-13 
12  205.4    
13  135.9    
14  168.2    
15 6.69 (d, J=2.1) 103.4 H-17 6.69 C-14, C-16, C-17 
16  164.9    
17 6.83 (dd, J=2.1,2.1) 116.7 H-15,18 6.83 C-13, C-15 
18 7.87 (d, J=8.7) 128.3 H-17 7.87 C-14, C-16 
19 4.67(d, J= 12) 54.5 H-11,21 4.67 C-11, C-12, C-21/C-25 
20  134.9    
21 7.15 (d, J= 9.0) 129.9 H-22 7.15 C-19, C-23, C-25 
22 6.57 (d, J= 8.4) 116.2 H-21 6.57 C-20, C-23 
23  156.8    
24 6.57 (d, J= 8.4) 116.3    
25 7.15 (d, J= 9.0) 129.9    
26  134.9    
27 7.15 (d, J= 9. 130.6    
28 6.57 (d, J=8.4) 116.2    
29  156.9    
30 6.57 (d, J=8.4) 116.3    
31 7.15 (d, J= 9.0) 130.6    
-OCH3 3.76 s                             56.2        3.76  
 
B and B’ values may be reversed 
 
 
 
 
 
52 
 
O
HO
OH
OH
OH
O
O
MeO
2
3
4
10
5
6
7
8
9
11
12
13
18
17
16
15
14
19
20
21
22
23
24
25
26
27
28
29
30
31
A C
A'
B'
B
H
H
H
H
COSY
HMBC
H
H
H
 
Figure 1a.Important HMBC’s (full arrow) and COSY (half arrow) correlations for compound 39 
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Figure 1b. Important NOESY correlations for compound 39 
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Such types of biflavonoids are relatively rare in nature, and 3-(1-(2,4-dihydroxyphenyl)-3,3-
bis(4-hydroxyphenyl)-1-oxopropan-2-yl)-7-methoxy-4H-chromen-4-one (Rhuschromone) is, to 
our knowledge, the first hydroxyphenyl chromen-4-one to be reported from Rhus natalensis and 
possibly within the entire Rhus genus. The other phenoxychromone to be isolated was 
chamaechromone (42) from the roots of Stellera chamaejasme L (Thymelaeaceae) (Masatake et 
al., 1984). Subsequently, R. Ghogomu et al., (1987) isolated Lophirone A (43), a 
phenoxychromone from the stem bark of Lophira lanceolata (Ochnaceae) and Calodenone (44) ( 
Messanga, et al., 1992) isolated from the stem bark of Ochna calodendron (Ochnaceae). The 
reported biological activity of the latter did not include any significant antibacterial activity. On 
the contrary Rhuschromone was found to possess a relatively high activity as an antimicrobial 
zone of inhibition (21mm). It was speculated that the activity observed may be associated with 
the unique positioning of the 7-OCH3 group in ring A. From a biogenetic point of view, 
Rhuschromone differs from known biflavonoids in having involved an aryl shift of ring B from 
one flavone unit to the next resulting to an isoflavone. The term ‘isobiflavonoid’ would best suit 
this class of compounds.  
O
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4.4. 2’, 4’-dihydroxychalcone-(4-O-5’’’)-4’’,2’’’,4’’’-trihydroxychalcone (40) 
Compound 40, was obtained as a yellow solid. MS indicated an ion at m/z 510.1212 (M+, 
calculated 510.1314) consistent with a molecular formula of C30H22O8. 
OH
OH
O
OH
HO
OH
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O
1
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1'
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3' 5'
6'
1''
4''
1'''
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3'''
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6'''
40
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The structure was established on the basis of 1D (1H, 13C and DEPT) and 2D-NMR experiments 
(COSY, NOESY, HSQC and HMBC) (Table 8, Appendix 2a-i). The 1H NMR spectrum 
(300MHz, CD3OD-d6) showed signals of a three ABC proton spin system observed at H-3’(δ 
6.31, d, J= 2.4 Hz) that had a long range meta-coupling with signal at H-5’ (δ 6.42, dd, 
J=9.0,2.4Hz), and H-6’ (δ 8.01,d, J=9.0 Hz) characteristic of a 1,2,4-trisubstituted benzene unit. 
There were two singlet signals integrating for one proton each observed at H-6’’’ (δ 7.94, s) and 
H-3’’’ (δ 6.61, s). Two pairs of the AA’BB’-type signals, where one pair was at H-2/6 (δ 7.75, d, 
J=8.41Hz) and H-3/5 (δ 6.96, d, J=8.8 Hz) and the other pair at H-2’’/6’’ (δ 7.67, d, J=8.4Hz) 
and H-3’’/5’’ (δ 6.87, d, J=8.7Hz), were observed for the two para-substituted phenolic moieties. 
The given data strongly suggested compound 40 to be a bichalcone. Signals of trans-alkene 
protons of the bichalcone system were not clearly observed due to weak resolution of some 
peaks. Multiplets at H-α (δ 7.57 m) and H-α’ (δ 7.68 m) for hydrogen protons connected to α and 
α’ carbons (δCH 118.3) could only be tentatively assigned.  
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The 13C NMR spectrum of compound 40 displayed signals for 30 carbon atoms which were 
edited by DEPT into 17 methines and 13 non-protonated carbons amongst which were two 
carbonyls and seven oxygenated carbons. The HMBC spectrum showed the chemical shift of a 
carbonyl group whose carbon signal had 3J interactions with the H-6’’’ singlet at (δ 7.94 s) and 
the H-β’ signal at (δ 7.85 d, J=15.3 Hz) and this was assigned to with the upfield C=O’ signal at 
δC 192.4. Likewise, the second H-β signal at (δ 7.83 d, J=15.3Hz) was correlated to the other 
C=O resonance at δC 192.0 (figure 2a). The presence of the two C=O at δ 192.0 and δ 192.4, 
allowed the proposal of the bichalcone structure (Table 8). NOESY irradiation gave some 
important information in establishing the inter-chalcone linkage in that the signals belonging to 
H-5’ and H-6’ of ring A of one of these chalcone moieties had no corresponding correlation with 
the signals for H-3’’’ and H-6’’’ of ring A’ of the other. The linkage was determined to be at C-4 
(δ 158.4) and C-5’’’ (δ 127.3) forming the C-4-O-5’’’connection. The 13C (DEPT), COSY and 
HMBC spectra results were in agreement with those of a chalcone reported on, to a great extent 
in the literature namely, Rhuschalcone II (Ladislaus et al., 2003) from the root bark of Rhus 
pyroides. The accompanying NMR data facilitated the proposal of a similar bichalcone as a 
constituent of the root bark of Rhus natalensis. The tentative structure of the chalcone was 
therefore deduced to be the 2’, 4’-dihydroxychalcone-(4-O-5’’’)-4’’,2’’’,4’’’-trihydroxychalcone 
(40) 
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Table 8. 1H NMR and 13C NMR data of compound 40 in CD3OD at 300MHz   
 
Position 
1H NMR 
(δ multiplicity, J) 
13C 
NMR    
(δ) 
COSY HMQC  HMBC 
1  129.9    
2 7.75 (d, J= 8.4) 128.8 H-3 7.75 C-β, C-3/5, C-4 
3 6.96 (d, J= 8.7) 115.6 H-2 6.96 C-1, C-2/6, C-4 
4  158.4    
5 6.96 (d, J= 8.7) 115.6 H-6 6.96 C-1, C-2/6, C-4 
6 7.75 (d, J= 8.4) 130.6 H-5 7.75 C-β, C-3/5, C-4 
1’  165.2    
2’  113.9    
3’ 6.31 (d, J= 2.4) 102.4 H-5’ 6.31 C-1’, C-2’, C-5’ 
4’  166.2    
5’ 6.42 (dd, J= 9.0,2.4) 108.1 H-3’, H-6’ 6.42 C-1’, C-3’ 
6’ 8.01 (d, J= 9.0) 132.1 H-5’ 8.01 C=O, C-2’, C-4’,  
1’’  129.1    
2’’ 7.67 (d, J= 8.4) 130.2 H-3’’ 7.67 C-β’, C-3’’/5’’, C-4’’ 
3’’ 6.87 (d, J= 8.7) 116.7 H-2’’ 6.87 C-1’’, C-2’’/6’’ 
4’’  160.3    
5’’ 6.87 (d, J= 8.7) 115.3 H-6’’ 6.87 C-1’’, C-2’’/6’’ 
6’’ 7.67 (d, J= 8.4) 128.0 H-5’’ 7.67 C-β’, C-3’’/5’’C-4’’ 
1’’’  113.3    
2’’’  160.4    
3’’’ 6.61 (s) 107.8  6.61 C-1’’’, C-5’’’ 
4’’’  157.9    
5’’’  127.3    
6’’’ 7.94 (s) 126.4  7.94 C-2’’’, C-4’’’, C=O 
α 7.57 (m) 118.3 H-β 7.57 C-1, C-β 
β 7.83 (d, J=15.3) 143.6 H-α 7.83 C-1, C-α, C2/6, C=O 
α’ 7.68 (m)  118.3 H-β’ 7.68 C-1’’, C-β’ 
β’ 7.85 (d, J=15.3) 144.8 H-α’ 7.85 C-α’, C=O’, C-2’’/6’’ 
C=O  192.0    
C=O’  192.4    
 
 
 
           
 
 
 
 
57 
 
 
OH
OH
O
OH
HO
OH
O
O 1
2'
4
1'
4'
3' 5'
6'
1''
4''
1'''
2'''
3'''
4'''
6'''
H
H
H
HHH
A'
A
B'
B
H
HMBC
NOESY
     
Figure 2a.Important HMBC correlations (full arrow) and NOESY (half arrow) for compound 40 
 
This is another biflavonoid that is of a relatively rare bichalcone class in nature, and is being 
reported for the first time as isolated from Rhus natalensis.  On the part of the biological activity, 
2’, 4’-dihydroxychalcone-(4-O-5’’’)-4’’,2’’’,4’’’-trihydroxychalcone (40), exhibited significant 
antibacterial activity (Table 6). It showed relative activity as an antimicrobial, zone of inhibition 
(17mm) though much lower than the standard chloramphenicol on Staphylococcus aureus. 
Reported biological activity of rhuschalcone II was carried out for in vitro primary cytotoxic 
screening using human tumor cell lines (Ladislaus, et al., 2003). Varying degrees of cytotoxicity 
activity were recorded.    
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4.5.    3-((Z)-heptadec-13-enyl) benzene-1, 2-diol (41) 
Compound 41, was obtained as a clear liquid, revealing a pseudo molecular ion [M+H] + at m/z 
347.2945, corresponding to the molecular formula C23H38O2 (calculated 347.2945). 
OH
OH
411'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
14'
15'
16'
17'
1
35
 
 
The structure was established on the basis of 1D (1H, 13C and DEPT) and 2D-NMR experiments 
(COSY and HMBC) (Table 9, Appendix 3a-h). The 1H and 13C NMR showed the typical pattern 
of a 5-alkenyl substituted catechol with a linear 17-carbon side chain containing one double bond 
at δ 5.33 (H-13’/H-14’), δ130.8 and 130.2 (C-13’/ C-14’), 14 methylene groups between δC 23.7 
and δC 36.9 and one methyl group resonating at H-17’ (δ 0.89 t) and C-17’ (δ 14.4) (Valcic et al., 
2002; Jin et al., 2006). The existence of a phenol ring originating from catechol could be 
identified with the signals between 6ppm and 7 ppm. Six aromatic carbons at C-1 (δ 158.3), C-2 
(δ 145.6), C-3 (δ 130.9), C-4 (δ 116.2), C-5 δ 120 and C-6 (δ 113.5) as well as three proton 
signals at H-4 (δ 6.63, d, J=7.2), H-5 (δ 7.05 t) and H-6 (δ 6.57, d, J=7.8) indicating a catechol 
moiety in compound 41. δH (600MHz, CD3OD), 0.89 (3H, t, Me), 1.29 (18H, (CH2)9),  2.03 ( 
4H, m, 2CH2CH=), 2.52 (2H, t, CH2Ar), 5.33 (2H, dd, CH=CH, J=5.4,9.6Hz), 6.63 (d, J=7.2, H-
4), 6.57 (d, J=7.8, H-6) and 7.05 (t, H-5).   
The first four positions 1’-4’ of the side chain were assigned by 1H, 13C (HMBC)-long range 
correlations, COSY and NOESY (Figure 3a and 3b).There was long range coupling between the 
proton H-14’ (δ5.33) and H-12’ (δ2.03).  
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The 13C peak selection offered that possibility of determining HSQC and the HMBC spectra for 
the crowded region of the methylene carbons of compound 41 (δ10-40ppm) with high resolution. 
HMBC correlations that are there between the protons of the terminal methyl group at δ0.89 and 
the carbons at δC23.7 and δC30.8 assisted in establishing the C-16’ and C-15’ positions 
respectively. There was a 2J1H-13C- connectivity between the latter carbon and the proton signal 
of H-14’ at δ5.33 which shows a 3J HMBC correlation with the allylic C-12’ (δ 28.1) that 
assisted locate the double bond at C-13’ (δ 130.8). This assignment was confirmed by HMBC 
correlation between both the olefinic resonance H-14’ (δ5.33) and C-16’at δ23.7 and the latter 
with the methyl group H-17’ (δ 0.89). Homo-nuclear decoupling experiments on the allylic 
protons as described in previous literature enabled establish the position of the double bond 
(Gonzales et al, 1996) and determination of the Z-configuration (J=9.6).  
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Figure 3b. Important COSY and NOESY (double arrow) 
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Table 9. 1H NMR and 13C NMR data of compound 41 in CD3OD at 600MHz   
Position 
 
1H NMR 
 δ, multiplicity, J 
13CNMR 
δ (ppm) 
HSQC HMBC 
 
1  158.3              
2  145.6  C-4, C-6  
3  130.9     
4 6.63 d, J=7.2 116.2 6.63 C-2, C-6 
5 7.05 t 120.7 7.05 C-1, C-3 
6 6.57 d, J=7.8 113.5 6.57 C-2, C-4 
1’ 2.52 t 36.9 2.52 C-2. C-3, C-4, C-2’ 
2’ 1.58, q 33.0 1.58 C-1’, C-3 
3’ 1.29 ov 30.3   
4’ 1.29 ov 30.4   
5’ 1.29 ov 30.6   
6’ 1.29 ov 30.7   
7’ 1.29 ov 30.7   
8’ 1.29 ov 30.7   
9’ 1.29 ov 30.7   
10’ 1.29 ov 30.7   
11’ 1.29 ov 32.6   
12’ 2.03 m 28.1  C-11’, C-13’, C-14  
13’ 5.33 dd, J=5.4, 9.6 130.8 5.33 C-12’, C-15 
14’ 5.33 dd, J=5.4, 9.6 130.2 5.33 C-12, C-15, C-16 
15’ 2.03 m 30.8   
16’ 1.37 ov 23.7   
17’ 0.89, t 14.4  C-15’, C-16’ 
Ov- overlapped by other signals 
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3-((Z)-heptadec-13-enyl) benzene-1, 2-diol (41) is a major constituent of the resulting 
monomeric urushiols extracted from the roots of Rhus natalensis. In addition to other compounds 
extracted from the plant, this catechol is the only one of its kind obtained from the hexane 
extract. Biological activity of the compound did not exhibit any major antibacterial activity. It 
was found to possess only a moderate to low activity as an antimicrobial zone of inhibition (9 
mm) as compared to the standard chloramphenicol. Previous literature reports that meta-
substituted catechol functionalities are present in a large number of natural compounds with 
beneficial effects on the human body. They have been used in the production of some anti-
hypertensive pharmaceuticals (Kieboom et al, 2001). Compound 41 is one of such natural 
products. 
 
In this study, a number of the crude extracts were active against both Gram-positive and Gram-
negative bacteria, but for the pure compounds, activity was observed only against Gram-positive 
bacteria. The activity against both types of bacteria may be indicative of the presence of a broad 
spectrum of antibiotics or simply general metabolic toxins in these extracts. The antibacterial 
activity of biflavonoids against both Gram-positive and Gram-negative bacteria has been 
reported. Activity against bacteria like S. aureus was demonstrated mainly by compounds that 
contained hydroxyl groups in ring B. Biflavonoid compounds having two to three hydroxyl 
groups in rings A or B were more active against such Gram-positive bacteria. It has been 
documented (Grosvenor, et al., 1995; Martinez, et al., 1996; Chariandy, et al., 1999; Stickler and 
King, 1992) that S. aureus is one of the bacteria most susceptible to plant extracts. Other 
biflavonoids are known to be active against antibiotic-resistant bacteria.  
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Such bacteria are inhibited by those compounds carrying hydroxyl groups in ring B, for example 
quercetin (27), and kaempherol (28). 
 
The results of the present investigation have clearly indicated that the antibacterial and antifungal 
activity vary with the different plant parts (Hoffman et al., 1993). This study is a preliminary 
evaluation of antimicrobial activity of R. natalensis. It indicates that the plant has the potential to 
generate novel metabolites. The crude extracts demonstrating anti-candidal activity could lead to 
the discovery of novel anti-candidal agents. The plant has demonstrated a broad spectrum of 
activity that may help discover new chemical classes of antibiotics that could serve as selective 
agents for the maintenance of animal or human health and provide biochemical tools for the 
study of infectious diseases. These findings provide yet another example of the validity of 
making more advantageous structural modifications of seemingly rather thoroughly examined 
anti-infective drug in further researches. Compound 39 with the name Rhuschromone, is a new 
biflavonoid that is naturally isolated and with high antibacterial activity.  
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CHAPTER 5 
CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion 
The research efforts on Rhus extracts indicate a promising potential for the plant family to 
provide renewable bio-products with the following desirable bioactivities: antimicrobial, 
antifungal, antimalarial, antiviral, antifibrogenic, antiinflammatory, antimutagenic, antioxidant, 
antithrombin, antitumorigenic, cytotoxic, hypoglycaemic, and leukopenic. More bioactive 
components can be extracted from the plant material using environmentally benign solvents like 
methanol, and water that allow for both food and industrial end-uses. A substantial opportunity 
exists to investigate the use of other good solvents like the sub-critical and super-critical liquids, 
ionic liquids among others for extracting bioactive components plus other phytochemicals in 
processing the residue for complete biomass conversion.  
 
This study validates and documents, in a systematic way, the antimicrobial properties of the 
genus Rhus used for many years by many people of the world. It also provides valuable 
information for further phytochemical isolation and characterization studies of active 
compounds, necessary for the development of new drugs. At present the search for compounds 
active against antibiotic-resistant strains of bacteria is continuing among the flavonoids, 
compounds which are non-toxic or have low toxicity (Narayana, et al., 2001). However, as this 
overview demonstrates, the previous work had focused on only a few members of this large plant 
family. In addition, not all of the species studied to date have been fully characterized for 
potential bioactivities.  
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Thus, there remains a significant research gap spanning the range from lead chemical discovery 
through process development and optimization in order to better understand the full bioactive 
potential of the Rhus genus as part of the global green technology based bio-product and bio-
process research programs. 
 
5.2 Recommendations 
 The results obtained from the parts of Rhus natalensis plant should be considered for 
further studies aimed at isolating and identifying more active compounds having 
discovered the antimicrobial activities observed in this research work. 
 Strong activity against Gram-positive bacteria particularly by the compounds extracted 
should make this plant a target for further studies aimed at discovering new and more 
potent antimicrobial drugs which are effective. 
 Further research could be carried out to screen for any immune boosting in the human 
body especially against viral attacks by drugs from this plant.  
 In vivo activities should be initiated as soon as in vitro results have provided clear 
evidence for proof of activity. 
  The dispensary details should be determined in order to provide the proper dosage for 
correct administration of such drugs. 
 The Government should offer support to sustainable harvesting of these medicinal plants 
and put systems in place enabling the marketing of such drugs obtained from this kind of 
plants. 
 Conservation measures of such plants, having proven antimicrobial activity, are very 
important. This is by conserving all the major forests from extinction. 
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 Further studies should be extended to other related species of the plant from the different 
geographical regions to evaluate their activity against microbials. 
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Appendix 1b 1H NMR of 39 
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Appendix 1c 1H NMR of 39 
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Appendix 1d DEPT 135 of 39 
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Appendix 1e DEPT of 39 
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Appendix 1f COSY of 39 
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Appendix 1g HMQC of 39 
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Appendix 1h HMBC of 39 
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Appendix 1i HMBC of 39 
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Appendix 1j HMBC of 39 
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Appendix 1k NOESY of 39 
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Appendix 2a 1H NMR of 40 
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Appendix 2b 1H NMR of 40 
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Appendix 2c DEPT of 40 
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Appendix 2d 13C in CD3OD of 40 
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Appendix 2e COSY of 40 
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Appendix 2h HMBC of 40 
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Appendix 2i NOESY of 40 
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Appendix 3a 1H NMR of 41 
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Appendix 3b 13C NMR of 41 
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Appendix 3c DEPT NMR of 41 
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Appendix 3d COSY NMR of 41 
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Appendix 3e HMBC NMR of 41 
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Appendix 3f HSQC NMR of 41 
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Appendix 3g HSQC NMR of 41 
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Appendix 3h NOESY NMR of 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
